For privately insured patients in U.S., OOP spending on diabetes-related supplies higher than insulin costs
TUESDAY, June 2, 2020 (HealthDay News) — For privately insured patients with type 1 diabetes, mean out-of-pocket spending is $2,414 per year, according to a research letter published online June 1 in JAMA Internal Medicine.
Kao-Ping Chua, M.D., Ph.D., from the University of Michigan Medical School in Ann Arbor, and colleagues estimated out-of-pocket spending for insulin and other health care services for privately insured patients with type 1 diabetes. Data were included for 65,192 patients, including 7,842 children (12 percent); 14,680 individuals were enrolled in high-deductible health plans.
Of the participants, 56.8 percent used insulin pumps, continuous glucose monitors, or both. The researchers found that the mean annual out-of-pocket spending was lower for insulin than for diabetes-related supplies ($435 versus $490). The mean overall annual out-of-pocket spending was $2,414; this spending exceeded $5,000 for 8 percent of patients. Eighteen percent of overall out-of-pocket spending was accounted for by insulin. There was variation in mean annual out-of-pocket spending for diabetes-related supplies among patients who used insulin pumps only, continuous glucose monitors only, both, or neither ($562, $472, $1,037, and $79, respectively). Children had higher use of diabetes technologies and higher out-of-pocket spending for diabetes-related supplies than adults. Higher out-of-pocket spending was seen in each category for patients enrolled in high-deductible health plans versus other plans.
“Findings suggest that substantial out-of-pocket burden may remain for patients with type 1 diabetes even if insulin cost-sharing is limited,” the authors write.
One author disclosed financial ties to the technology industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
2021 to 2026 Saw Increase in State Funding for Suicide Prevention
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets
Time-Restricted Eating May Help Patients With Type 1 Diabetes
Cancer-Attributable Costs High for Seniors, Vary With Cancer Phase, Type, Race
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026
Cancer Survivors Have Lower Levels of Physical Activity